Journal of Shanghai Jiao Tong University (Medical Science) ›› 2022, Vol. 42 ›› Issue (3): 364-368.doi: 10.3969/j.issn.1674-8115.2022.03.015

• Review • Previous Articles     Next Articles

Advances in gut microbiota in the pathogenesis and treatment of inflammatory bowel disease

LI Bowen(), LIU Ningning(), WANG Hui()   

  1. Shanghai Jiao Tong University School of Public Health, Shanghai 200025, China
  • Received:2021-11-04 Online:2022-03-28 Published:2022-05-09
  • Contact: LIU Ningning,WANG Hui E-mail:maylee59@foxmail.com;liuningning@shsmu.edu.cn;huiwang@shsmu.edu.cn
  • Supported by:
    National Key R&D Program of China(2020YFA0907200);National Natural Science Foundation of China(81630086)

Abstract:

The gut microbiota plays a critical role in human health. Inflammatory bowel disease (IBD) is an immunological disease caused by various environmental factors, including the gut microbiota, in genetically susceptible individuals. Although most studies have indicated the role of gut microbiota and their metabolites in contribution to the occurrence and development of intestinal diseases by inducing inflammation and immune disorders. However, the causal relationship between microbiota and IBD pathogenesis cannot be determined. In this review, the alteration of bacterial, fungal and viral microbiota and the potential functional pathways during IBD pathogenesis are summarized. Besides, the current therapeutic approaches targeting microbiota and the promising perspectives are introduced.

Key words: inflammatory bowel disease (IBD), dysbiosis, microbiota, fungus

CLC Number: